| Literature DB >> 27095252 |
Brenda Happell1, Chris Platania-Phung1, Cadeyrn J Gaskin2,3, Robert Stanton4.
Abstract
BACKGROUND: People with severe mental illness have poorer physical health, experience disparities in physical health care, and lead significantly shorter lives, compared to the general population. Routine metabolic monitoring is proposed as a method of identifying risk factors for metabolic abnormalities. Efforts to date suggest routine metabolic monitoring is both incomplete and ad-hoc, however. This present study reports on the recent implementation of a routine metabolic monitoring form at a mental health service in regional Australia.Entities:
Keywords: Cardiometabolic; Mental health service; Monitoring; Physical health; Severe mental illness
Mesh:
Year: 2016 PMID: 27095252 PMCID: PMC4837626 DOI: 10.1186/s12888-016-0814-9
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Demographic and psychiatric diagnostic differences between consumers for whom the metabolic monitoring form had and had not been used
| Total sample ( | Form used ( | Form not used ( | Effect size |
| |
|---|---|---|---|---|---|
| Age, mean (SD) years | 41.4 (14.6) | 41.4 (14.3) | 41.5 (14.8) |
| .902 |
| Sex | φ = .12 | .001 | |||
| Males, | 421 (58.4) | 175 (41.6) | 246 (58.4) | ||
| Females, | 300 (41.6) | 89 (29.7) | 211 (70.3) | ||
| Diagnosis (ICD-10)a | Cramer’s | <.001 | |||
| Schizophrenia (F20), | 305 (42.3) | 159 (60.7) | 146 (33.1) | ||
| Bipolar disorder (F31), | 84 (11.7) | 23 (27.4) | 61 (72.6) | ||
| Depressive disorders (F32, F33), | 81 (11.2) | 17 (21.0) | 64 (79.0) | ||
| Anxiety disorders (F41), | 40 (5.5) | 7 (17.5) | 33 (82.5) | ||
| Other, | 193 (26.8) | 56 (29.0) | 137 (71.0) |
aDiagnosis data were missing for 18 (2.5 %) consumers
SD standard deviation; ICD- 10
Data recorded in the metabolic monitoring form at baseline
| Measure | Observation recorded – | Observation not recorded – | |
|---|---|---|---|
| Anthropometry | Height | 223 (85.4) | 38 (14.6) |
| Weight | 228 (87.4) | 33 (12.6) | |
| Body mass index | 192 (73.6) | 69 (26.4) | |
| Waist circumference | 142 (54.4) | 119 (45.6) | |
| Blood pressure | Blood pressure | 218 (83.5) | 43 (16.5) |
| Fasting blood glucose | Fasting blood glucose | 157 (60.2) | 104 (39.8) |
| Lipids | Cholesterol | 147 (56.3) | 114 (43.7) |
| Low density lipoprotein | 127 (48.7) | 134 (51.3) | |
| High density lipoprotein | 153 (51.7) | 126 (48.3) | |
| Triglycerides | 144 (55.2) | 117 (44.8) | |
| Liver function | Alanine aminotransferase | 173 (66.3) | 88 (33.7) |
| Aspartate aminotransferase | 171 (65.5) | 90 (34.5) | |
| Gamma-glutamyl transpeptidase | 169 (64.8) | 92 (35.2) | |
| Renal function | Urea | 173 (66.3) | 88 (33.7) |
| Creatinine | 172 (65.9) | 89 (34.1) |
Medication-specific observations recorded in the metabolic monitoring forms at baseline
| Measurea | Observation recorded – | Observation not recorded – | |
|---|---|---|---|
| Endocrine | Prolactin levelb | 27 (10.3) | 234 (89.7) |
| Sodium valproate | Full blood count | 8 (3.1) | 253 (96.9) |
| Valproate level | 26 (10.0) | 235 (90.0) | |
| Carbamazepine | Full blood count | 1 (0.4) | 260 (99.6) |
| Carbamazepine level | 3 (1.1) | 258 (98.9) | |
| Lithium | Thyroid function test | 54 (20.7) | 207 (79.3) |
| Lithium level | 3 (1.1) | 258 (98.9) | |
| Clozapine | Clozapine level | 40 (15.3) | 221 (84.7) |
aSpace is also provided on the form to record observations of cardiac function, including electrocardiogram (rate, rhythm, abnormality), echocardiogram (if consumers are on Clozapine), and troponin. No forms contained observations for these measures
bInstructions on form are to record if consumer is on Risperidone or Amisulpride